| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/0264-410X(90)90094-3 |
| P698 | PubMed publication ID | 2204243 |
| P2093 | author name string | Cryz SJ | |
| Levine MM | |||
| Tall BD | |||
| Tramont EC | |||
| Formal SB | |||
| Hale TL | |||
| Herrington DA | |||
| Van de Verg L | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Salmonella typhi | Q22111431 |
| Shigella sonnei | Q6382438 | ||
| P304 | page(s) | 353-357 | |
| P577 | publication date | 1990-08-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. | |
| P478 | volume | 8 |
| Q57929967 | A Novel Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge |
| Q34522511 | Acid resistance in enteric bacteria |
| Q35193532 | Advances in the development of bacterial vector technology |
| Q35047221 | Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors |
| Q40186741 | Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery |
| Q33608118 | Characterization of B-cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural infection |
| Q37067264 | Circulating Gut-Homing (α4β7+) Plasmablast Responses against Shigella Surface Protein Antigens among Hospitalized Patients with Diarrhea |
| Q93075052 | Clinical endpoints for efficacy studies |
| Q54246807 | Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score. |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q91801435 | Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints |
| Q91801457 | Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies |
| Q35548702 | Construction and characterization of a live attenuated vaccine candidate against Shigella dysenteriae type 1. |
| Q34545910 | Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine |
| Q35469131 | Development of Shigella sonnei live oral vaccines based on defined rfbInaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide. |
| Q55333715 | Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput Shigella Serum Bactericidal Assay. |
| Q54572055 | Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. |
| Q39423812 | Effect of antipyretic therapy on the duration of illness in experimental influenza A, Shigella sonnei, and Rickettsia rickettsii infections |
| Q35896020 | Enteric pathogens as vaccine vectors for foreign antigen delivery |
| Q37166078 | Epidemic spread of Shigella sonnei shigellosis and evidence for development of immunity among children attending day-care centers in a communal settlement (Kibbutz) |
| Q37066116 | Establishment of a Shigella sonnei human challenge model in Thailand |
| Q36764372 | Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects |
| Q34068059 | Gut-Homing Conventional Plasmablasts and CD27(-) Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans |
| Q50104933 | Histopathological study of rabbit intestinal mucosa infected with a hybrid strain of Shigella dysenteriae 1 carrying LPS biosynthesis genes of Salmonella enterica serovar typhimurium |
| Q57173696 | Human microbial challenge: the ultimate animal model |
| Q99616552 | Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G |
| Q40706785 | Immune responses in Vietnamese children after a single dose of the auxotrophic, live Shigella flexneri Y vaccine strain SFL124. |
| Q40460000 | Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. |
| Q40267400 | Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models. |
| Q38648043 | In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity. |
| Q34280918 | Intracellular bacteria as targets and carriers for vaccination |
| Q72678992 | Is protection against shigellosis induced by natural infection with Plesiomonas shigelloides? |
| Q50039350 | Live non-invasive Shigella dysenteriae 1 strain induces homologous protective immunity in a guinea pig colitis model. |
| Q36689023 | Live-attenuated Shigella vaccines |
| Q35772614 | Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines. |
| Q34129475 | Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector |
| Q50169617 | Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains |
| Q36365336 | Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis |
| Q36718111 | Oral Delivery of Antigens in Live Bacterial Vectors |
| Q54558147 | Oral carrier vaccines: New tricks in an old trade |
| Q34120926 | Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults |
| Q37125747 | Presence of specific immunoglobulin A-secreting cells in peripheral blood after natural infection with Shigella sonnei |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q35210784 | Prospects for Human Mucosal Vaccines |
| Q78171100 | Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines |
| Q42227472 | Recent trends in the epidemiology of shigellosis in Israel |
| Q38665950 | Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe. |
| Q34008338 | Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults |
| Q40501431 | Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial |
| Q34006223 | Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel |
| Q35523144 | Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers |
| Q36945836 | Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. |
| Q35528270 | Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG. |
| Q35225017 | Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm. |
| Q37477191 | Shigella Vaccine Development: Finding the Path of Least Resistance |
| Q34202171 | Shigella isolates from the global enteric multicenter study inform vaccine development |
| Q56383780 | Shigellosis |
| Q36989057 | Small-animal model to measure efficacy and immunogenicity of Shigella vaccine strains |
| Q35227831 | Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a |
| Q40087889 | Stable expression of Shigella dysenteriae serotype 1 O-antigen genes integrated into the chromosome of live Salmonella oral vaccine vector Ty21a |
| Q34000330 | Strategy for cross-protection among Shigella flexneri serotypes |
| Q33607442 | Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid |
| Q52657631 | T cell mediated immunity induced by the live-attenuated Shigella flexneri 2a vaccine candidate CVD 1208S in humans. |
| Q36845284 | Targeting and controlled release of antigens for the effective induction of secretory antibody responses |
| Q38035961 | The Shigella human challenge model |
| Q40469794 | Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. |
| Q33876803 | Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602 |
| Q37167473 | Vaccines and milk immunoglobulin concentrates for prevention of infectious diarrhea |
Search more.